-
EGTA for Endothelial Calcium-Causality Studies
2026-08-20
EGTA and egtazic acid provide a selective way to interrogate extracellular calcium in endothelial inflammation models. This article connects EGTA assay design to the Piezo1–Talin1–YAP mechanism, emphasizing causal controls, handling limits, and interpretation rather than routine protocol repetition.
-
CHK1 Inhibition in Breast Cancer by ER/PR Status
2026-08-19
The reference study shows that CHK1 inhibition cannot be applied uniformly across breast cancer subtypes: it enhances adriamycin sensitivity in ER−/PR−/HER2− models but acts mainly as a single-agent treatment strategy in ER+/PR+/HER2− models. Its integrated use of clinical datasets, functional assays, and transcriptome analysis links these divergent responses to distinct cell-cycle and apoptosis pathways.
-
PP 1: Src Family Tyrosine Kinase Inhibitor
2026-08-19
A scenario-based guide to using PP 1 (Src family tyrosine kinase inhibitor), SKU A8215, in cell viability, proliferation, and signaling assays. It explains solvent control, concentration selection, orthogonal readouts, data interpretation, and practical criteria for selecting a reliable research-grade inhibitor.
-
ACE Inhibitors and Aminopeptidase Selectivity
2026-08-18
The reference study re-evaluated how bestatin and several metallopeptidase inhibitors affect the related cell-surface aminopeptidases AP-N, AP-A, and AP-W. Its head-to-head comparison showed that inhibitor selectivity is enzyme- and scaffold-dependent, with important implications for interpreting pharmacological experiments involving ACE inhibitors and zinc aminopeptidases.
-
Oligomycin A for Reliable Cell Assays
2026-08-18
Learn how Oligomycin A, SKU A5588, can clarify mitochondrial contributions to viability, proliferation, and cytotoxicity data. This scenario-based guide covers assay compatibility, solvent handling, metabolic adaptation, interpretation, and practical vendor-selection criteria.
-
Amiloride (MK-870) Ion Transport Workflow
2026-08-17
Use Amiloride (MK-870) as a time-controlled perturbation for epithelial sodium channel, PC2, uPAR, and uptake studies—not as a stand-alone proof of pathway identity. This workflow combines dose-response design, orthogonal readouts, and troubleshooting strategies for sodium channel research, cystic fibrosis research, hypertension research, and cellular endocytosis modulation.
-
Belinostat (PXD101) Workflow for Cancer Assays
2026-08-17
Belinostat (PXD101) combines potent pan-HDAC activity with measurable cell-cycle and growth effects in bladder and prostate cancer models. This workflow shows how to separate proliferation arrest from cell killing, improve dose-response reliability, and troubleshoot solubility, timing, and assay-readout problems.
-
Lithium, Rab11a, and Exosomal Wnt10a in Osteogenesis
2026-08-16
The reference study identifies a mechanism in which lithium enhances Rab11a-dependent secretion of exosomal Wnt10a from bone mesenchymal stem cells, thereby activating Wnt/β-catenin signaling and osteogenesis. Its comparison of lithium-conditioned exosomes and GelMA hydrogel delivery provides a framework for investigating engineered extracellular vesicles in bone repair.
-
Tropifexor (LJN452) FXR Research Workflow
2026-08-15
Build reproducible gut–liver experiments with Tropifexor (LJN452), from sub-nanomolar FXR activation to intestinal barrier and metabolic readouts. This practical workflow connects receptor-focused perturbation with triacetin absorption data while keeping mechanistic claims appropriately bounded.
-
Cy3-UTP Workflows for Fluorescent RNA Studies
2026-08-14
Cy3-UTP enables direct fluorescent RNA production for imaging, RNA-protein interaction studies, condensate assays, and detection workflows. This guide connects practical in vitro transcription RNA labeling with the replication-organelle clustering mechanism revealed in a β-coronavirus study, while highlighting controls and troubleshooting steps that protect RNA function.
-
Thymoquinone: From Ferroptosis Probe to Translation
2026-08-14
Thymoquinone is emerging as a mechanistically versatile probe for studying doxorubicin-induced cardiac injury. This article connects Nrf2/HO-1 activation, ferroptosis mitigation, oxidative stress control, and translational assay design while defining the evidence boundaries for cardioprotective research.
-
Dual Luciferase Reporter Gene System for MYC2
2026-08-13
Use a two-reporter workflow to separate pathway-driven promoter changes from variation in transfection, cell number, or reagent delivery. This practical guide translates the tomato MYC2–LBD40/42–CRL3BPM4 findings into controlled reporter experiments while clarifying where mammalian assay compatibility limits cross-species interpretation.
-
Losartan Workflows for Vascular and Renal Research
2026-08-13
Losartan provides a reversible, receptor-focused way to interrogate angiotensin II signaling in vascular smooth muscle cells, hypertension models, and podocyte injury. This workflow extends those established applications into a mechanistic diabetic nephropathy assay built around AT1R trafficking, COL4 accumulation, CREB activation, and MMP-2 regulation.
-
Butylhydroxyanisole (BHA) in Oxidative Stress Research
2026-08-12
Butylated hydroxyanisole (BHA) is a synthetic phenolic antioxidant used to manipulate redox conditions in biochemical and cellular assays. Its solvent limitations, product-specific storage guidance, and nonselective radical chemistry make matched controls essential for reliable oxidative stress research.
-
Z-DEVD-FMK: Interpreting Caspase-3 Assays
2026-08-12
Z-DEVD-FMK is a cell-permeable caspase-3 inhibitor for dissecting apoptosis, calpain-dependent proteolysis, and neuronal injury. This guide adds a critical assay-design perspective by showing how caspase inhibition can clarify, but not by itself define, the boundary between apoptosis and pyroptosis.